中华皮肤科杂志 ›› 2021, Vol. 54 ›› Issue (11): 943-950.doi: 10.35541/cjd.20210547

• 指南与共识 • 上一篇    下一篇

中国儿童银屑病生物治疗专家共识(2021)

中华医学会皮肤性病学分会儿童学组    中国医师协会皮肤科医师分会儿童皮肤病学组    中华医学会儿科学分会皮肤性病学组    中国康复医学会皮肤病康复专业委员会儿童皮肤病康复学组   

  1. 中华医学会皮肤性病学分会儿童学组    中国医师协会皮肤科医师分会儿童皮肤病学组    中华医学会儿科学分会皮肤性病学组    中国康复医学会皮肤病康复专业委员会儿童皮肤病康复学组
  • 收稿日期:2021-07-29 修回日期:2021-09-13 发布日期:2021-11-01
  • 通讯作者: 马琳;王华 E-mail:bch_maleen@aliyun.com; huawang@hospital.cqmu.edu.cn

Treatment of pediatric psoriasis with biological agents: a Chinese expert consensus statement (2021)

Group on Children, Chinese Society of Dermatology; Group on Pediatric Dermatology, China Dermatologist Association; Dermatology and Venereology Group, Chinese Pediatric Society, Chinese Medical Association; Pediatric Dermatology Rehabilitation Group, Chinese Association of Rehabilitation Dermatology   

  1. Group on Children, Chinese Society of Dermatology; Group on Pediatric Dermatology, China Dermatologist Association; Dermatology and Venereology Group, Chinese Pediatric Society, Chinese Medical Association; Pediatric Dermatology Rehabilitation Group, Chinese Association of Rehabilitation Dermatology
  • Received:2021-07-29 Revised:2021-09-13 Published:2021-11-01
  • Contact: Ma Lin; Wang Hua E-mail:bch_maleen@aliyun.com; huawang@hospital.cqmu.edu.cn

摘要: 【摘要】 对于中重度儿童银屑病,若外用药治疗无法控制病情,临床则需要考虑系统治疗。儿童属于生物制剂应用的特殊人群,应用的剂量、疗效及安全性与成人不尽相同。为此,我国儿童银屑病诊疗领域部分专家依据国内外指南及共识、相关文献及临床经验,经过深入讨论,制定本共识。从生物制剂的应用原则、应用方法、疗效及安全性、疗程及停药时机、用药前筛查及用药过程中监测等方面提供指导性意见,希望为我国中重度儿童银屑病患者生物制剂的应用提供参考依据。

关键词: 银屑病, 生物制剂, 儿童, 治疗, 专家共识

Abstract: 【Abstract】 For moderate to severe pediatric psoriasis, if disease condition cannot be controlled by topical treatments, systemic treatments should be considered in clinical practice. Children are a special population for the application of biologics, and different from adults in terms of dosage, efficacy, and safety of biologics. Based on Chinese and international guidelines and consensus, relevant literature and current clinical experience, a group of experts in the field of pediatric psoriasis developed this consensus after in-depth discussions. This consensus provides guidance regarding application principles and methods, efficacy and safety, and treatment duration of biologics, as well as time-to-withdrawal, pre-treatment screening and treatment monitoring. It is hoped that this consensus will provide a reference for rational application of biologics among children with moderate to severe psoriasis in China.

Key words: Psoriasis, Biological agents, Child, Treatment, Consensus